ACS in perspective - The importance of secondary prevention
Estimating the economic cost
Deloitte Access Economics was commissioned by AstraZeneca Australia to estimate the economic cost of acute coronary syndrome (ACS) and to explore the extent of investment in secondary prevention of ACS.
Coronary heart disease (CHD) accounts for greater morbidity in Australia than any other single disease and nearly one fifth of all deaths in Australia (AIHWa, 2010). Acute coronary syndrome (ACS) is a subset of CHD and is defined across a range of medical conditions which result in the acute reduction of blood flow to the heart. ACS encompasses chest pain at rest (unstable angina) and heart attack (acute myocardial infarction – AMI).
Despite ongoing clinical management and treatment of patients who initially present at hospital with ACS, repeat ACS events often occur. Within the first six months following initial ACS diagnosis, up to one third of patients may present with repeat ACS, however, the time frame for repeat ACS may extend to many years (Jia et al, 2005).
Deloitte Access Economics was commissioned by AstraZeneca Australia to investigate the epidemiological profile of ACS in Australia, estimate the economic cost of ACS including repeat ACS, and to explore the extent of investment in secondary prevention of ACS.
Published: November 2011